{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-105679","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2023-04-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.880174+00:00","generated_at":"2026-06-16T23:31:46.800770+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Agios director Paul Clancy to retire; Jeff Capello elected to board, to chair Audit Committee","bullets":["Paul Clancy will not stand for re-election at 2023 Annual Meeting; ceases as Audit Committee chair and Compensation & People Committee member.","Jeff Capello elected as class II director effective at 2023 Annual Meeting; appointed Audit Committee chair.","Capello receives $50,000/yr director cash retainer plus $20,000/yr for Audit Chair role; initial equity grant of stock options ($472,500 Black-Scholes) and RSUs ($157,500).","Capello enters into standard indemnification agreement with the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-105679","json":"https://secwatch.observer/filing/0001193125-23-105679.json","markdown":"https://secwatch.observer/filing/0001193125-23-105679.md","text":"https://secwatch.observer/filing/0001193125-23-105679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523105679/0001193125-23-105679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523105679/d499411d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T23:31:46.800770+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"004572d115","claim":"Paul Clancy resigned as Director at AGIOS PHARMACEUTICALS, INC..","evidence_excerpt":"On April 17, 2023, Paul Clancy notified Agios Pharmaceuticals, Inc. (the “Company”) of his decision not to stand for re-election to the Board of Directors (the “Board”) of the Company when his current term expires at the Company’s 2023 Annual Meeting of Stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523105679/0001193125-23-105679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8d83b86235","claim":"Jeff Capello was elected as Director at AGIOS PHARMACEUTICALS, INC..","evidence_excerpt":"On April 18, 2023, the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Corporate Governance Committee”), elected Jeff Capello as a director, effective as of the date of the Corporation’s 2023 Annual Meeting of Stockholders (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523105679/0001193125-23-105679-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}